FRNM
Freenome, Inc. Common stock
NASDAQ · Financial Services · Financial - Conglomerates · US
$11.30
−1.48%Oct 20, 2026, 19:01 UTC
FRNM announced the commercial availability of SimpleScreen Lung, a laboratory-developed test that screens for lung and colorectal cancer from one blood draw and can be ordered alone or alongside its FDA-approved SimpleScreen CRC test; SimpleScreen Lung itself has not been reviewed or approved by the FDA.
Source:Oct 11, 2026, 17:00 UTC
FRNM announced that it will present validation data on an updated version of its SimpleScreen CRC blood-based screening test at the ACG 2026 Annual Meeting in Nashville.
Source: